SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/
The scientific team of SunRock Biopharma.
SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock will benefit from Chime Biologics’ global-standard GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones.
“We are proud to collaborate with SunRock Biopharma on this promising anti-CCR9 antibody (SRB5) for inflammatory bowel disease, a condition that significantly impacts patients worldwide. This partnership reflects our commitment to applying our global-standard quality and comprehensive experiences in manufacturing biologics to accelerate the development of innovative therapies. We look forward to contributing to the long-term mission of SunRock Biopharma to develop innovative antibodies against highly invasive tumors with an urgent clinical need in oncology,” said Dr.Jimmy Wei, President of Chime Biologics.
Dr. Laureano Simón, CEO of SunRock Biopharma, added “This collaboration with Chime Biologics reinforces our strategy of working with world-class partners across every stage of development. Chime’s technical expertise and industrial quality standards will help us scale SRB5 under optimal conditions. SRB5 has a distinctive biological profile that could transform the therapeutic landscape in IBD and potentially in highly aggressive CCR9-expressing tumors. This agreement is a critical step toward clinical validation.”
About SunRock Biopharma
SunRock Biopharma is a Spanish biotechnology company developing first-in-class and best-in-class therapeutic antibodies targeting emerging disease drivers in oncology and immune-mediated inflammatory diseases. Its approach focuses on identifying targets with a strong role in tumor progression or inflammation, generating fully human or humanized antibodies with enhanced functional profiles, and advancing them toward early clinical stages for licensing to global pharma partners.
SunRock’s pipeline includes monoclonal antibodies, antibody-drug conjugates (ADCs), and other innovative formats. SunRock collaborates with academic institutions and industry partners across Europe, the U.S., and Asia.
More information: www.sunrockbiopharma.com
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers’ success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. For more information, please visit www.chimebiologics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251019831972/en/
Contacts
Press Contact – SunRock Biopharma
media@sunrockbiopharma.com
Press Contact – Chime Biologics
info@chimebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku opens Rigaku Technology Center Taiwan20.10.2025 18:00:00 EEST | Press release
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a new group company in Taiwan, in 2025. A facility within RTTW, Rigaku Technology Center Taiwan (hereinafter RTC-TW), began full-scale operation in October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020130286/en/ Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park RTTW will assume duties formerly managed by Rigaku Taiwan Branch (RCTW), established in 2024. As Rigaku’s base of operations in Chinese-speaking East Asia, RTTW aims to strengthen customer support and advance sustainable growth in the region. RTC-TW will serve as an engineering base for advancing R&D, customer support, and joint development. The facility will include a clean room that replicates actual production environments, along w
InterSystems and Google Cloud Integrate InterSystems HealthShare with Google Cloud’s Healthcare API20.10.2025 17:00:00 EEST | Press release
InterSystems, a creative data technology provider managing over one billion health records worldwide, today announced a new partnership that integrates InterSystems HealthShare with Google Cloud. Announced at HLTH, this collaboration aims to deliver a scalable, real-time, harmonized data foundation for generative and agentic AI applications. The partnership addresses one of the most pressing challenges in healthcare IT: fragmented and inconsistent data. By combining InterSystems expertise in data harmonization, identity resolution, and interoperability with Google Cloud’s broad suite of AI-enabled analytics and search capabilities and secure infrastructure, healthcare organizations can now unlock the full potential of AI with clean, unified, and actionable data on a proven, enterprise-grade cloud platform. “AI is transforming healthcare, but it can only succeed when it’s grounded in reliable, actionable data,” said Don Woodlock, head of Global Healthcare Solutions at InterSystems. “By
Wolters Kluwer supports SOCAR’s digital transformation journey with launch of Enablon Control of Work solution at Pirallahi Island upstream facility20.10.2025 16:30:00 EEST | Press release
Wolters Kluwer today announced that the State Oil Company of the Azerbaijan Republic (SOCAR) has successfully launched the Enablon Control of Work (CoW) solution at its first upstream oil gathering location in the Abşeronneft Oil and Gas Production Department (OGPD), located on Pirallahi Island. In line with its digital transformation efforts, the company shifts from manual, paper-based systems to fully integrated digital workflows for managing work permits, isolations, risk assessments, and safety protocols. As the fully state-owned enterprise responsible for oil and natural gas production from both onshore and offshore fields in the Azerbaijani sector of the Caspian Sea, SOCAR plays a vital role in the nation’s energy infrastructure. It operates Azerbaijan’s only oil refinery, a gas processing plant, and oversees several strategic oil and gas export pipelines. With the rollout of the Enablon CoW solution, SOCAR is strengthening its commitment to standardizing safety practices across
Lenovo Advances the AI-Enabled Workforce with Agentic AI: Trusted, Proven, and Ready to Deliver ROI20.10.2025 16:00:00 EEST | Press release
As enterprises race to capture value from AI, Lenovo today unveiled new agentic AI capabilities as the centerpiece of its AI-Enabled Workforce portfolio, a complete suite of devices, services, and lifecycle solutions that turn AI investments into measurable business value. According to IDC, enterprises are already realizing nearly $4 in return for every $1 invested in generative AI, and by 2027 agentic AI is expected to double workforce productivity worldwide1 – evidence that organizations are moving from AI experimentation to tangible results. This marks a turning point where enterprises are shifting from piloting AI to embedding intelligent automation across their workforces, and Lenovo is helping lead this transformation. With Lenovo’s agentic AI capabilities, organizations can deploy digital agents that work independently or alongside employees to manage workflows, automate tasks, and support smarter decisions within trusted security guardrails. Backed by Lenovo’s AI infrastructure
TagEnergy Selects Sitetracker to Accelerate Renewable Energy Growth20.10.2025 16:00:00 EEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that TagEnergy, a fast-growing renewable energy producer, has selected Sitetracker to standardize operations and scale its portfolio across multiple markets. The move underscores TagEnergy’s commitment to delivering clean energy projects more efficiently while maintaining the highest standards of quality and transparency. TagEnergy develops and operates wind, solar, and battery storage projects across Europe, Japan and Australia, and is on track to double its size in the next three to four years. To support this growth, the company required a modern, flexible platform to unify processes across departments and countries, eliminate reliance on spreadsheets, and provide real-time visibility into project performance. By deploying Sitetracker, TagEnergy will: Get more done faster by eliminating manual tasks, standardizing workflows, and enabling teams to manage more projects wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom